Blueprint Medicines Corporation (BPMC)

Market Cap	8.37B
Revenue (ttm)	562.12M
Net Income (ttm)	-155.73M
Shares Out	64.73M
EPS (ttm)	-2.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,481,011
Open	129.32
Previous Close	129.33
Day's Range	129.00 - 129.35
52-Week Range	73.04 - 129.49
Beta	0.90
Analysts	Buy
Price Target	127.82 (-1.14%)
Earnings Date	Jul 31, 2025

About BPMC

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medul...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 30, 2015
• Employees: 649
• Stock Exchange: NASDAQ
• Ticker Symbol: BPMC
• Website: https://www.blueprintmedicines.com

Financial Performance

In 2024, Blueprint Medicines's revenue was $508.82 million, an increase of 104.04% compared to the previous year's $249.38 million. Losses were -$67.09 million, -86.77% less than in 2023.

Analyst Summary

According to 20 analysts, the average rating for BPMC stock is "Buy." The 12-month stock price target is $127.82, which is a decrease of -1.14% from the latest price.

Price Target

$127.82

(-1.14% downside)

Analyst Consensus: Buy